scholarly journals Impact of disease duration and β‐cell reserve on the efficacy of switching to iGlarLixi in adults with type 2 diabetes on glucagon‐like peptide‐1 receptor agonist therapy: Exploratory analyses from the LixiLan‐G trial

2020 ◽  
Vol 22 (9) ◽  
pp. 1567-1576 ◽  
Author(s):  
Stefano Del Prato ◽  
Juan Pablo Frias ◽  
Lawrence Blonde ◽  
Vanita R. Aroda ◽  
Niam Shehadeh ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Receptor Agonist ◽  
Disease Duration ◽  
Agonist Therapy ◽  
Β Cell ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals The time-varying cardiovascular benefits of glucagon like peptide-1 agonist (GLP-RA)therapy in patients with type 2 diabetes mellitus: A meta-analysis of multinational randomized trials

2021 ◽  
Author(s):  
Salil Deo ◽  
◽  
David McAllister ◽  
Naveed Sattar ◽  
Jill Pell
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Receptor Agonist ◽  
Meta Analysis ◽  
Agonist Therapy ◽  
Number Of Patients ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Review question / Objective: P - patients with type 2 diabetes melllitus already receiving routine medical therapy; I - patients receiving glucagon like peptide 1 receptor agonist (GLP1 receptor agonist) therapy (semaglutide, dulaglutide, liraglutide, exenatide, lixisenatide, efpeglenatide, abiglutide); C - patients receiving standard therapy for diabetes mellitus but not receiving GLP1 agonist therapy; O - composite end point as per invididual trial, cardiovascular mortality, all-cause mortality, myocardial infarction, stoke. Condition being studied: Type 2 diabetes mellitus. Study designs to be included: Randomised controlled trials which enroll a large number of patients (defined as > 500) and are multinational in origin. Studies included will need to have published Kaplan and Meier curves for the end-points presented in the manuscript.

Sign in / Sign up

Export Citation Format

Share Document